Active	Status	Sponsor type	Region	Phase	Filter
9 Active 1 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Guntinas-Lichius, Orlando
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	Recruiting	3	510	Europe, Canada, Japan, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	10/26	02/27
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC	Recruiting	3	500	Europe, Japan, US, RoW	JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy	Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA	Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged	06/26	06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Withdrawn	2	130	Europe, US, RoW	RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab	Replimune Inc., Bristol-Myers Squibb	Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	03/26	06/26